MLTX250117C30000
- 0.00
- 0.000.00%
MoonLake Immunotherapeutics Newsroom
MoonLake Immunotherapeutics Announces Board Changes and Incentives
Clear Street Launches Healthcare & Biotechnology Equity Research
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $77
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $65
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology
MoonLake Immunotherapeutics' Promising SLK Therapy Forecasts Strong Market Performance and Stock Potential
UCB Gets FDA Approval for Bimzelx for Hidradenitis Suppurativa
MoonLake Immunotherapeutics Management to Meet With Oppenheimer
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $73
MoonLake Immunotherapeutics' Promising Phase 3 Trials for PsA Treatment Drives Buy Rating
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $104
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Advancements and Strong Market Potential
MoonLake Immunotherapeutics Announces First Patients Screened in IZAR Program
Express News | MoonLake Immunotherapeutics: Topline Primary Endpoint Readout at Week 16 for Phase 3 Izar Program Expected in H1 2026
MoonLake Immunotherapeutics Starts Phase 3 IZAR Program of the Nanobody Sonelokimab in Patients With Active Psoriatic Arthritis
Express News | MoonLake Immunotherapeutics Starts Phase 3 Izar Program of the Nanobody® Sonelokimab in Patients With Active Psoriatic Arthritis
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $62